Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis-A post hoc analysis of the LANDMARK study.

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-06-01 DOI:10.1111/1744-9987.13954

Kiryu Yoshida, Takuya Mizukami, Masafumi Fukagawa, Tadao Akizawa, Hokuto Morohoshi, Takehiko Sambe, Akiko Takeshima, Hidetoshi Ito, Hiroaki Ogata, Naoki Uchida

{"title":"Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis-A post hoc analysis of the LANDMARK study.","authors":"Kiryu Yoshida, Takuya Mizukami, Masafumi Fukagawa, Tadao Akizawa, Hokuto Morohoshi, Takehiko Sambe, Akiko Takeshima, Hidetoshi Ito, Hiroaki Ogata, Naoki Uchida","doi":"10.1111/1744-9987.13954","DOIUrl":null,"url":null,"abstract":"Introduction: The clinical benefit of vitamin D receptor activators (VDRA) in patients with well-controlled secondary hyperparathyroidism undergoing dialysis remains unclear.Methods: This post hoc analysis of the LANDMARK study investigates if VDRA use is associated with cardiovascular benefits. Data of 2135 patients undergoing hemodialysis who were at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity-score matching.Results: The hazard ratio (HR) for VDRA use was 0.99 (95% confidence interval [CI]: 0.67-1.46; p = 0.945) for cardiovascular events and 0.89 (95% CI: 0.62-1.28; p = 0.541) for all-cause mortality at baseline. Among patients who always used VDRA, the HR was 1.12 (95% CI: 0.67-1.89; p = 0.666) for cardiovascular events and 1.11 (95% CI: 0.67-1.85; p = 0.688) for all-cause mortality compared to those who never used VDRA.Conclusion: The use of VDRA does not reduce the risks of cardiovascular events or all-cause mortality in patients on dialysis with well-controlled secondary hyperparathyroidism.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13954","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The clinical benefit of vitamin D receptor activators (VDRA) in patients with well-controlled secondary hyperparathyroidism undergoing dialysis remains unclear.

Methods: This post hoc analysis of the LANDMARK study investigates if VDRA use is associated with cardiovascular benefits. Data of 2135 patients undergoing hemodialysis who were at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity-score matching.

Results: The hazard ratio (HR) for VDRA use was 0.99 (95% confidence interval [CI]: 0.67-1.46; p = 0.945) for cardiovascular events and 0.89 (95% CI: 0.62-1.28; p = 0.541) for all-cause mortality at baseline. Among patients who always used VDRA, the HR was 1.12 (95% CI: 0.67-1.89; p = 0.666) for cardiovascular events and 1.11 (95% CI: 0.67-1.85; p = 0.688) for all-cause mortality compared to those who never used VDRA.

Conclusion: The use of VDRA does not reduce the risks of cardiovascular events or all-cause mortality in patients on dialysis with well-controlled secondary hyperparathyroidism.

查看原文本刊更多论文

维生素D受体激活剂对血液透析患者心血管事件的影响——LANDMARK研究的事后分析

维生素D受体激活剂(VDRA)在接受透析的控制良好的继发性甲状旁腺功能亢进患者中的临床益处尚不清楚。方法:这项LANDMARK研究的事后分析调查了VDRA的使用是否与心血管益处相关。采用倾向-评分匹配的Cox比例风险模型对2135例有血管钙化风险的血液透析患者的数据进行分析。结果:使用VDRA的风险比(HR)为0.99(95%可信区间[CI]: 0.67-1.46;p = 0.945)和0.89 (95% CI: 0.62-1.28;P = 0.541)的全因死亡率基线。在一直使用VDRA的患者中，HR为1.12 (95% CI: 0.67-1.89;p = 0.666)和1.11 (95% CI: 0.67-1.85;p = 0.688)，与从未使用VDRA的患者相比，全因死亡率明显降低。结论:在控制良好的继发性甲状旁腺功能亢进透析患者中，使用VDRA并不能降低心血管事件或全因死亡率的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.